Cover Image
市場調查報告書

美國的癌症生物標記市場上的機會:2011-2021年

United States Cancer Biomarker Market Opportunities, 2011 - 2021

出版商 Pharmaion 商品編碼 354418
出版日期 內容資訊 英文 117 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
美國的癌症生物標記市場上的機會:2011-2021年 United States Cancer Biomarker Market Opportunities, 2011 - 2021
出版日期: 2016年03月15日 內容資訊: 英文 117 Pages
簡介

美國的癌症患者數,2015年達165萬8,370人。由於該國癌症發病率的增加,更優秀診斷的癌症生物標記需求也擴大。美國酒精消費量的增加,高抽煙率,不健康的飲食習慣,身體不動 (長坐) 的生活方式等,使癌症的風險增大。癌症生物標記研究的政府資金增加,預計與藥物研發、臨床實驗的生物標記的利用擴大互相結合,促進今後5年美國的癌症生物標記市場。

本報告提供美國的癌症生物標記市場相關調查,各市場規模、佔有率、預測,分析技術、終端用戶、癌症類型分析,市場趨勢的變化,新的機會,競爭趨勢,及參與企業簡介等彙整資料。

第1章 產品概要

第2章 調查方法

第3章 分析師的見解

第4章 全球癌症生物標記市場概要

第5章 美國的癌症生物標記市場概要

第6章 美國的癌症生物標記市場展望

  • 市場規模與預測
    • 以金額為準
  • 市場佔有率與預測
    • 各分析技術 (免疫檢測、體學技術、細胞遺傳學的技術、成像技術、生物資訊學)
    • 各應用領域 (藥物研發、開發、診斷、預後、風險評估、其他)
    • 各終端用戶 (臨床研究委外機構 (CRO) 、醫藥品廠商、醫療保健供應商)
    • 各癌症類型 (肺癌、乳癌、大腸癌、其他)
    • 各地區
    • 各企業

第7章 美國的癌症生物標記免疫檢測分析技術市場展望

  • 市場規模與預測
    • 以金額為準
  • 市場佔有率與預測
    • 各類型 (免疫組織化學 (IHC) 、酵素免疫分析法 (ELISA) 、流式細胞技術)

第8章 美國的癌症生物標記的體學分析技術市場展望

  • 市場規模與預測
    • 以金額為準
  • 市場佔有率與預測
    • 各類型 (基因學、蛋白質體學、其他)

第9章 美國的癌症生物標記細胞遺傳學的分析技術市場展望

  • 市場規模與預測
    • 以金額為準
  • 市場佔有率與預測
    • 各類型 (螢光In-situ雜合反應 (FISH) 、其他)

第10章 美國的癌症生物標記成像分析技術市場展望

  • 市場規模與預測
    • 以金額為準
  • 市場佔有率與預測
    • 各類型 (正子輻射斷層攝影法 (PET) 、核磁共振影像 (MRI) 、電腦斷層攝影法 (CT) 、其他)

第11章 市場動態

  • 促進要素
  • 課題

第12章 市場趨勢與發展

  • 個人化醫療的生物標記的參與
  • 作為替代指標的生物標記
  • 新產品開發
  • 適合乳癌的預後、預測生物標記檢驗
  • 產品改良

第13章 政策和法規環境

第14章 美國經濟簡介

第15章 競爭環境

  • Abbott Laboratories
  • Affymetrix, Inc.
  • Roche Diagnostics Corporation
  • Illumina, Inc.
  • Hologic, Inc.
  • Merck & Co. Inc.
  • Agilent Technologies
  • Qiagen Sciences, Inc.
  • Becton, Dickinson and Company
  • Alere, Inc.

第16章 策略性建議

圖表

目錄
Product Code: P019

As per the American Cancer Society estimates, the number of cancer cases in the United States is estimated to have stood at 1,658,370 in 2015. With growing incidence rate of cancer in the country, the demand for cancer biomarker for better diagnosis is also increasing at a robust pace. In the US, growing consumption of alcohol and high smoking prevalence coupled with poor dietary habits and sedentary lifestyle of the citizens is increasing cancer risk among the country's population. Moreover, increasing government funding for cancer biomarker research, coupled with growing use of biomarkers in drug discovery development and clinical trials is further anticipated to fuel cancer biomarker market in the US over the next five years.

“United States Cancer Biomarker Market Opportunities, 2011 - 2021” report studies the market size and share of various segments and sub-segments of the cancer biomarker market in the United States during the period 2011 - 2021. In the study, the market has been categorized into five broader segments that include Immunoassay, Omics Technology, Cytogenetic Technology, Imaging Technology and Bioinformatics.

The market dynamics section of the report elaborates the factors that are driving the market as well as the challenges inhibiting growth. The research study also includes insights of the key market trends, a detailed analysis of the changing competitive landscape, and revenue forecasts for each segment and sub-segment.

All this information is provided to assist the established market players and new entrants in taking their strategic decisions, thereby aiding them in strengthening their market position in a highly competitive cancer biomarker market in the United States.

“United States Cancer Biomarker Market Opportunities, 2011 - 2021” report elaborates the following aspects of cancer biomarker market in the United States:

  • United States Cancer Biomarker Market Size, Share& Forecast
  • Segmental Analysis - By Profiling Technology (Immunoassay, Omics Technology, Cytogenetic Technology, Imaging Technology & Bioinformatics), By Application (Drug Discovery and Development, Diagnosis, Prognostic, Risk Assessment & Others), By End User (Contract Research Organizations (CROs) and Drug Manufacturers & Healthcare Providers), By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer & Others)
  • Policy & Regulatory Landscape
  • Changing Market Trends & Emerging Opportunities
  • Competitive Landscape & Strategic Recommendations

Why You Should Buy This Report?

  • To identify the on-going trends and anticipated growth in the next five years
  • To gain competitive knowledge of leading market players
  • To avail 10% customization in the report without any extra charges and get the research data or trends added in the report as per the buyer's specific needs

Key Questions This Study Will Answer

  • What would be the segmental and regional growth trends in the United States cancer biomarker market in the coming years?
  • What are the most important growth drivers and opportunities in the market?
  • Which profiling technology is preferred the most?
  • What strategies should market competitors employ to gain share in mature segments of the United States cancer biomarker market?
  • What are the competitor profiles in this market and how do they compete for market share?

Report Methodology

The information contained in this report is based upon both primary and secondary sources. Primary research included interviews with cancer biomarker manufacturers and industry experts. Secondary research included an exhaustive search of relevant publications like company annual reports, financial reports and other proprietary databases.

Table of Contents

1. Product Overview

2. Research Methodology

3. Analyst View

4. Global Cancer Biomarker Market Overview

5. United States Cancer Biomarker Market Overview

6. United States Cancer Biomarker Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Profiling Technology (Immunoassay, Omics Technology, Cytogenetic Technology, Imaging Technology & Bioinformatics)
    • 6.2.2. By Application (Drug Discovery and Development, Diagnosis, Prognostics, Risk Assessment & Others)
    • 6.2.3. By End User (Contract Research Organizations (CROs) and Drug Manufacturers, & Healthcare Providers)
    • 6.2.4. By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, & Others)
    • 6.2.5. By Region
    • 6.2.6. By Company

7. United States Cancer Biomarker Immunoassay Profiling Technology Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type (Immunohistochemistry (IHC), Enzyme-linked Immunosorbent Assay (ELISA) & Flow Cytometry)

8. United States Cancer Biomarker Omics Profiling Technology Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type (Genomics, Proteomics & Others)

9. United States Cancer Biomarker Cytogenetic Profiling Technology Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type (Fluorescent In-situ Hybridisation (FISH) & Others)

10. United States Cancer Biomarker Imaging Profiling Technology Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type (Positron Emission Tomography (PET), Magnetic Resonance Imaging (MRI), Computed Tomography (CT) & Others)

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends and Developments

  • 12.1. Involvement of Biomarker in Personalised Medicine
  • 12.2. Biomarkers as Surrogate Endpoints
  • 12.3. New Product Developments
  • 12.4. Prognostic and Predictive Biomarker Test for Breast Cancer
  • 12.5. Product Enhancements

13. Policy and Regulatory Landscape

14. United States Economic Profile

15. Competitive Landscape

  • 15.1. Abbott Laboratories
  • 15.2. Affymetrix, Inc.
  • 15.3. Roche Diagnostics Corporation
  • 15.4. Illumina, Inc.
  • 15.5. Hologic, Inc.
  • 15.6. Merck & Co. Inc.
  • 15.7. Agilent Technologies
  • 15.8. Qiagen Sciences, Inc.
  • 15.9. Becton, Dickinson and Company
  • 15.10. Alere, Inc.

16. Strategic Recommendation

List of Figures

  • Figure 1: United States Cancer Biomarker Market Size, By Value, 2011-2021F (USD Billion)
  • Figure 2: United States Cancer Biomarker Market Share, By Profiling Technology, By Value, 2011-2021F
  • Figure 3: United States Cancer Biomarker Market Share, By Application, By Value, 2011-2021F
  • Figure 4: United States Cancer Biomarker, By End User, By Value, 2011-2021F
  • Figure 5: United States Number of Contract Research Organisations (CROs), By Type, 2012
  • Figure 6: United States Cancer Biomarker, By Cancer Type, By Value, 2011-2021F
  • Figure 7: United States Estimated Number of New Lung & Bronchus Cancer Cases, By Sex, 2015 & 2016F
  • Figure 8: United States Estimated Number of New Breast Cancer Cases, By Sex, 2015 & 2016F
  • Figure 9: United States Female Breast Cancer Incidence Rate (per 100,000 population), By State, 2012
  • Figure 10: United States Cancer Biomarker Market Size, By Region, By Value, 2011-2015 (USD Billion)
  • Figure 11: United States Cancer Biomarker Market Size, By Region, By Value, 2016-2021 (USD Billion)
  • Figure 12: United States Cancer Biomarker Market Share, By Region, By Value, 2011-2021F
  • Figure 13: United States Cancer Biomarker Market Share, By Company, By Value, 2015 & 2021F
  • Figure 14: United States Cancer Biomarker Immunoassay Profiling Technology Market Size, By Value, 2011-2021F (USD Billion)
  • Figure 15: United States Cancer Biomarker Immunoassay Profiling Technology Market Share, By Type, By Value, 2011-2021F
  • Figure 16: United States Cancer Biomarker Omics Profiling Technology Market Size, By Value, 2011-2021F (USD Billion)
  • Figure 17: United States Cancer Biomarker Omics Profiling Technology Market Share, By Type, By Value, 2011-2021F
  • Figure 18: United States Cancer Biomarker Cytogenetic Profiling Technology Market Size, By Value, 2011-2021F (USD Billion)
  • Figure 19: United States Cancer Biomarker Cytogenetic Profiling Technology Market Share, By Type, By Value, 2011-2021F
  • Figure 20: United States Cancer Biomarker Imaging Profiling Technology Market Size, By Value, 2011-2021F (USD Billion)
  • Figure 21: United States Cancer Biomarker Imaging Profiling Technology Market Share, By Type, By Value, 2011-2021F
  • Figure 22: United States Cancer Incidence, By Cancer Type, 2012, 2015 & 2020F (Million)

List of Tables

  • Table 1: United States Partial List of Cancer Biomarkers, By Cancer Type
  • Table 2: United States Partial List of Lung Cancer Biomarker, By Cancer Type, 2015
  • Table 3: United States Partial List of Metastatic Breast Cancer Biomarker, 2015
  • Table 4: United States Partial List of Colorectal Cancer Biomarker, 2015
  • Table 5: Southern United States Partial List of Clinical Research Companies, By State, 2015
  • Table 6: US Midwest Region Partial List of Clinical Research Companies, By State, 2015
  • Table 7: Partial List of Pharmacogenomic Cancer Biomarkers in Labelling of FDA Approved Drugs
Back to Top